Literature DB >> 24795391

An encouraging progress report on the treatment of progeria and its implications for atherogenesis.

Junko Oshima1, Fuki M Hisama2, George M Martin2.   

Abstract

Entities:  

Keywords:  Editorials; atherosclerosis; clinical trial; farnesyltransferase; genetics; humans; progeria

Mesh：

Substances：

Year:  2014        PMID： 24795391      PMCID： PMC4322865          DOI： 10.1161/CIRCULATIONAHA.114.010648

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  21 in total

1.  Lamin a truncation in Hutchinson-Gilford progeria.

Authors:  Annachiara De Sandre-Giovannoli; Rafaëlle Bernard; Pierre Cau; Claire Navarro; Jeanne Amiel; Irène Boccaccio; Stanislas Lyonnet; Colin L Stewart; Arnold Munnich; Martine Le Merrer; Nicolas Lévy
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

2.  Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.

Authors:  Leslie B Gordon; Joe Massaro; Ralph B D'Agostino; Susan E Campbell; Joan Brazier; W Ted Brown; Monica E Kleinman; Mark W Kieran
Journal:  Circulation       Date:  2014-05-02       Impact factor: 29.690

3.  Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.

Authors:  Kan Cao; John J Graziotto; Cecilia D Blair; Joseph R Mazzulli; Michael R Erdos; Dimitri Krainc; Francis S Collins
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

4.  Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.

Authors:  Leslie B Gordon; Monica E Kleinman; David T Miller; Donna S Neuberg; Anita Giobbie-Hurder; Marie Gerhard-Herman; Leslie B Smoot; Catherine M Gordon; Robert Cleveland; Brian D Snyder; Brian Fligor; W Robert Bishop; Paul Statkevich; Amy Regen; Andrew Sonis; Susan Riley; Christine Ploski; Annette Correia; Nicolle Quinn; Nicole J Ullrich; Ara Nazarian; Marilyn G Liang; Susanna Y Huh; Armin Schwartzman; Mark W Kieran
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

5.  Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.

Authors:  Maria Eriksson; W Ted Brown; Leslie B Gordon; Michael W Glynn; Joel Singer; Laura Scott; Michael R Erdos; Christiane M Robbins; Tracy Y Moses; Peter Berglund; Amalia Dutra; Evgenia Pak; Sandra Durkin; Antonei B Csoka; Michael Boehnke; Thomas W Glover; Francis S Collins
Journal:  Nature       Date:  2003-04-25       Impact factor: 49.962

6.  Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome.

Authors:  Paola Scaffidi; Tom Misteli
Journal:  Nat Med       Date:  2005-03-06       Impact factor: 53.440

7.  Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy.

Authors:  Claire L Navarro; Annachiara De Sandre-Giovannoli; Rafaëlle Bernard; Irène Boccaccio; Amandine Boyer; David Geneviève; Smail Hadj-Rabia; Caroline Gaudy-Marqueste; Henk Sillevis Smitt; Pierre Vabres; Laurence Faivre; Alain Verloes; Ton Van Essen; Elisabeth Flori; Raoul Hennekam; Frits A Beemer; Nicole Laurent; Martine Le Merrer; Pierre Cau; Nicolas Lévy
Journal:  Hum Mol Genet       Date:  2004-08-18       Impact factor: 6.150

8.  Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria.

Authors:  Mohamed X Ibrahim; Volkan I Sayin; Murali K Akula; Meng Liu; Loren G Fong; Stephen G Young; Martin O Bergo
Journal:  Science       Date:  2013-05-16       Impact factor: 47.728

9.  Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome.

Authors:  Robert D Goldman; Dale K Shumaker; Michael R Erdos; Maria Eriksson; Anne E Goldman; Leslie B Gordon; Yosef Gruenbaum; Satya Khuon; Melissa Mendez; Renée Varga; Francis S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

10.  Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts.

Authors:  Bidisha Saha; Alexander Cypro; George M Martin; Junko Oshima
Journal:  Aging Cell       Date:  2014-02-05       Impact factor: 9.304
View more
  2 in total

1.  The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

Authors:  Hagen Sjard Bachmann; Werner Meier; Andreas du Bois; Rainer Kimmig; Jan Dominik Kuhlmann; Winfried Siffert; Jalid Sehouli; Kerstin Wollschlaeger; Jens Huober; Peter Hillemanns; Alexander Burges; Barbara Schmalfeldt; Behnaz Aminossadati; Pauline Wimberger
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

2.  A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells.

Authors:  Leigh Atchison; Haoyue Zhang; Kan Cao; George A Truskey
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.